Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic
University Clinical Centre, Department of Hematology and Transplantology, Gdansk
Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo
1<sup>st</sup> Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
4<sup>th</sup> Department of Medicine – Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Faculty of Medicine, Krakow
Department of Clinical Oncology, Medical Faculty, Medical University of Plovdiv, Plovdic, Bulgaria
Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine
Oncopeptides AB, Stockholm
Oncopeptides AB, Stockholm
Oncopeptides AB, Stockholm
Oncopeptides AB, Stockholm
Dana-Farber Cancer Institute, Boston, MA
Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca
Vol. 109 No. 3 (2024): March, 2024